1. World Health Organization. Malaria Geneva, Switzerland: WHO; 2019 [cited 2019 29 July]. Available from: https://www.who.int/news-room/fact-sheets/detail/malaria.
2. Orish V, Afutu L, Ayodele O, Likaj L, Marinkovic A, Sanyaolu A. A 4-Day Incubation Period of Plasmodium falciparum Infection in a Nonimmune Patient in Ghana: A Case Report. Open Forum Infect Dis. 2019;6(1):ofy169-ofy.
3. Hong NV, Delgado-Ratto C, Thanh PV, Van den Eede P, Guetens P, Binh NT, et al. Population Genetics of Plasmodium vivax in Four Rural Communities in Central Vietnam. PLoS neglected tropical diseases. 2016;10(2):e0004434.
4. Goldlust SM, Thuan PD, Giang DDH, Thang ND, Thwaites GE, Farrar J, et al. The decline of malaria in Vietnam, 1991–2014. Malaria Journal. 2018;17(1):226.
5. Thanh NV, Thuy-Nhien N, Tuyen NTK, Tong NT, Nha-Ca NT, Dong LT, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin–piperaquine in the south of Vietnam. Malaria Journal. 2017;16(1):27.
6. Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet (London, England). 2004;363(9402):18-22.
7. World Health Organization. Guidelines for the treatment of malaria. Third edition Geneva, Switzerland: WHO; 2015 [cited 2019 5 August]. Available from: https://www.who.int/malaria/publications/atoz/9789241549127/en/.
8. Vietnam Minstry of Health. Guideline for diagnosis and treatment of malaria [in Vietnamese]: VietnamMinstryofHealth; 2007 [cited 2019 Oct 14]. Available from: https://vanbanphapluat.co/quyet-dinh-339-qd-byt-huong-dan-chuan-doan-dieu-tri-benh-sot-ret.
9. Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. The Lancet Infectious diseases. 2017;17(5):491-7.
10. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin Resistance in Plasmodium falciparum Malaria. N Engl J Med 2009. 2009;361:455-67.
11. Menard D, Fidock DA. Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia. The Lancet Infectious diseases. 2019.
12. National Institute of Malariology, Parasitology and Entomology. Guideline for the use of Pyramax in treating patients with malaria infection Hanoi, Vietnam: NIMPE; 2019 [cited 2020 26 February]. Available from: http://nimpe.vn/userfiles/file/Pyramax/h%C6%B0%E1%BB%9Bng%20d%E1%BA%ABn.pdf.
13. Nsanzabana C, Djalle D, Guérin PJ, Ménard D, González IJ. Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape. Malaria journal. 2018;17(1):75-.
14. Thriemer K, Hong NV, Rosanas-Urgell A, Phuc BQ, Ha DM, Pockele E, et al. Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central Vietnam. Antimicrob Agents Chemother. 2014;58(12):7049-55.
15. Brasil P, de Pina Costa A, Pedro RS, da Silveira Bressan C, da Silva S, Tauil PL, et al. Unexpectedly long incubation period of Plasmodium vivax malaria, in the absence of chemoprophylaxis, in patients diagnosed outside the transmission area in Brazil. Malaria Journal. 2011;10(1):122.
16. World Health Organization. Methods for surveillance of antimalarial drug efficacy Geneva, Switzerland: WHO; 2009 [cited 2019 5 August]. Available from: https://www.who.int/malaria/publications/atoz/9789241597531/en/.
17. Vietnam Ministry of Health. Guideline for diagnosis and treatment of malaria 2013 [in Vietnamese] Hanoi, Vietnam: Ministry of Health; 2013 [cited 2020 26 February]. Available from: https://thuvienphapluat.vn/van-ban/the-thao-y-te/Quyet-dinh-3232-QD-BYT-2013-huong-dan-chan-doan-dieu-tri-benh-Sot-ret-207776.aspx.
18. Vietnam Ministry of Health. Guideline for diagnosis and treatment of malaria 2016 [in Vietnamese] Hanoi, Vietnam: Ministry of Health; 2016 [cited 2019 5 August]. Available from: https://thuvienphapluat.vn/van-ban/The-thao-Y-te/Quyet-dinh-4845-QD-BYT-Huong-dan-chan-doan-dieu-tri-benh-Sot-ret-2016-321533.aspx.
19. World Health Organization. Antimalarial drug efficacy and drug resistance Geneva, Switzerland: WHO; 2018 [cited 2020 26 February]. Available from: https://www.who.int/malaria/areas/treatment/drug_efficacy/en/.
20. Huynh HQ. An update on drug-resistant Plasmodium falciparum malaria in Vietnam and worldwide [in Vietnamese] Quy Nhon, Vietnam: Institute of Malariology, Parasitology and Entomology QuyNhon; 2017 [cited 2019 11 August ]. Available from: http://www.impe-qn.org.vn/impe-qn/vn/portal/InfoDetail.jsp?area=58&cat=1067&ID=11105.
21. Thien HV, Chien VT, Anh TK. Severe malaria in a provincial hospital in Vietnam. Lancet (London, England). 1990;336(8726):1316.
22. Goldlust SM, Thuan PD, Giang DDH, Thang ND, Thwaites GE, Farrar J, et al. The decline of malaria in Vietnam, 1991-2014. Malaria journal. 2018;17(1):226.
23. Kar NP, Kumar A, Singh OP, Carlton JM, Nanda N. A review of malaria transmission dynamics in forest ecosystems. Parasit Vectors. 2014;7:265-.
24. Lindsay SW, Martens WJ. Malaria in the African highlands: past, present and future. Bulletin of the World Health Organization. 1998;76(1):33-45.
25. Bui TC, Markham CM, Ross MW, Williams ML, Beasley RP, Tran LTH, et al. Dimensions of gender relations and reproductive health inequity perceived by female undergraduate students in the Mekong Delta of Vietnam: a qualitative exploration. International Journal for Equity in Health. 2012;11(1):63.
26. Thanh PV, Van Hong N, Van Van N, Van Malderen C, Obsomer V, Rosanas-Urgell A, et al. Epidemiology of forest malaria in Central Vietnam: the hidden parasite reservoir. Malaria journal. 2015;14:86-.
27. Kitchen AD, Chiodini PL. Malaria and blood transfusion. Vox sanguinis. 2006;90(2):77-84.
28. Alavi SM, Alavi L, Jaafari F. Outbreak investigation of needle sharing-induced malaria, Ahvaz, Iran. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2010;14(3):e240-2.
29. Rogerson SJ. Management of malaria in pregnancy. Indian J Med Res. 2017;146(3):328-33.
30. Muhindo MK, Kakuru A, Jagannathan P, Talisuna A, Osilo E, Orukan F, et al. Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malaria Journal. 2014;13(1):32.
31. World Health Organization. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2000;94 Suppl 1:S1-90.
32. Camponovo F, Bever CA, Galactionova K, Smith T, Penny MA. Incidence and admission rates for severe malaria and their impact on mortality in Africa. Malaria journal. 2017;16(1):1-.
33. Arévalo-Herrera M, Lopez-Perez M, Medina L, Moreno A, Gutierrez JB, Herrera S. Clinical profile of Plasmodium falciparum and Plasmodium vivax infections in low and unstable malaria transmission settings of Colombia. Malaria Journal. 2015;14(1):154.
34. Saravu K, Rishikesh K, Kamath A. Determinants of mortality, intensive care requirement and prolonged hospitalization in malaria - a tertiary care hospital based cohort study from South-Western India. Malaria journal. 2014;13:370-.
35. Gomes AP, Vitorino RR, Costa AdP, Mendonça EGd, Oliveira MGdA, Siqueira-Batista R. Malária grave por Plasmodium falciparum. Revista Brasileira de Terapia Intensiva. 2011;23:358-69.
36. Hänscheid T. Current strategies to avoid misdiagnosis of malaria. Clin Microbiol Infect. 2003;9(6):497-504.
37. Hase R. Diagnostic delay for imported malaria: A case of Plasmodium falciparum malaria misdiagnosed as common cold. J Gen Fam Med. 2017;19(1):27-9.
38. Al Farsi F, Chandwani J, Mahdi AS, Petersen E. Severe imported malaria in an intensive care unit: A case series. IDCases. 2019;17:e00544-e.
39. Asma U-e, Taufiq F, Khan W. Prevalence and clinical manifestations of malaria in Aligarh, India. Korean J Parasitol. 2014;52(6):621-9.
40. Woodford J, Shanks GD, Griffin P, Chalon S, McCarthy JS. The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study. The American journal of tropical medicine and hygiene. 2018;98(4):1113-9.
41. Woodford J, Shanks GD, Griffin P, Chalon S, McCarthy JS. The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study. Am J Trop Med Hyg. 2018;98(4):1113-9.
42. Al Farsi F, Chandwani J, Mahdi AS, Petersen E. Severe imported malaria in an intensive care unit: A case series. IDCases. 2019;17:e00544.
43. Choi IH, Hwang PH, Choi SI, Lee DY, Kim MS. Delayed Diagnosis of Falciparum Malaria with Acute Kidney Injury. J Korean Med Sci. 2016;31(9):1499-502.
44. Trampuz A, Jereb M, Muzlovic I, Prabhu RM. Clinical review: Severe malaria. Crit Care. 2003;7(4):315-23.
45. Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS microbiology reviews. 2017;41(1):34-48.
46. Commey J, Quarm-Goka B, Agyepong I. Persistent fever in severe malaria in children. The Central African journal of medicine. 1994;40(9):257-60.
47. Ouji M, Augereau JM, Paloque L, Benoit-Vical F. Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination. Parasite. 2018;25:24.
48. Nsanzabana C. Resistance to Artemisinin Combination Therapies (ACTs): Do Not Forget the Partner Drug! Tropical medicine and infectious disease. 2019;4(1).
49. van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. The Lancet Infectious diseases. 2019.
50. Hawkes M, Conroy AL, Kain KC. Spread of Artemisinin Resistance in Malaria. New England Journal of Medicine. 2014;371(20):1944-5.
51. Rasmussen C, Nyunt MM, Ringwald P. Artemisinin-Resistant Plasmodium falciparum in Africa. The New England journal of medicine. 2017;377(3):305-6.
52. Worldwide Antimalarial Resistance Network DPSG. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med. 2013;10(12):e1001564-e.
53. Mahase E. Malaria drugs left ineffective by spread of multidrug resistant parasites in southeast Asia. BMJ. 2019;366:l4807.
54. Vietnam Minstry of Health. Guideline for diagnosis and treatment of malaria 2009 [in Vietnamese] Hanoi, Vietnam: Vietnam Ministry of Health; 2009 [cited 2019 5 Aug]. Available from: https://vanbanphapluat.co/quyet-dinh-4605-q-c3-90-byt-huong-dan-chan-doan-va-dieu-tri-sot-ret.
55. Roseau JB, Pradines B, Paleiron N, Vedy S, Madamet M, Simon F, et al. Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient. Malaria journal. 2016;15:479-.
56. Hodel EM, Kay K, Hayes DJ, Terlouw DJ, Hastings IM. Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. Malaria journal. 2014;13:138-.
57. Moore BR, Batty KT, Andrzejewski C, Jago JD, Page-Sharp M, Ilett KF. Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model. Antimicrob Agents Chemother. 2008;52(1):306-11.
58. Tarning J, Zongo I, Somé FA, Rouamba N, Parikh S, Rosenthal PJ, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther. 2012;91(3):497-505.
59. Hoglund RM, Workman L, Edstein MD, Thanh NX, Quang NN, Zongo I, et al. Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLoS Med. 2017;14(1):e1002212-e.
60. Sowunmi A, Adewoye EO, Gbotsho GO, Happi CT, Sijuade A, Folarin OA, et al. Factors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children. Malaria Journal. 2010;9(1):53.
61. Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev. 2017;41(1):34-48.